- Does Tiger Woods' Latest Disgrace Mark a New Low for the Golf Business?
- Delta CEO, Backing Obama, Declares 'We Are a Nation of Immigrants'
- The Least Educated States in America
- Galena, Shunned by Wall Street, Forced to Seek Pricey Vulture Financing
- Black Friday Scorecard: Kmart Gets a 'C' for Light Crowds, Unsold Inventory
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for health care investors.
Martin Shkreli, the ousted CEO of Retrophin, received $3 million from selling company stock but delayed disclosure for two months, a new SEC filing shows.
The scandal-ridden Galena, still under active SEC investigation, was unable to muster sufficient interest from institutional investors.
BioMarin is betting that its experience in securing approvals for "orphan-disease" drugs can help Prosensa win approval for drisapersen, an experimental treatment for Duchenne muscular dystrophy.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales.
Healthcare investors are watching closely the race between Clovis and AstraZeneca to develop competing, targeted lung cancer drugs.
The experimental drug from Agios, designed to attack the "metabolism" of cancer cells, has demonstrated early but strong clinical responses in a study involving patients with advanced leukemia.
Using stem cells to repair damaged hearts is a great story, but proof remains elusive.
The new migalastat data compliment earlier esults from successful phase III study announced in August by Amicus.